Literature DB >> 30949914

Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.

Periklis Tsiros1, Frederic Y Bois2, Aristides Dokoumetzidis3, Georgia Tsiliki4, Haralambos Sarimveis5.   

Abstract

The aim of this study is to benchmark two Bayesian software tools, namely Stan and GNU MCSim, that use different Markov chain Monte Carlo (MCMC) methods for the estimation of physiologically based pharmacokinetic (PBPK) model parameters. The software tools were applied and compared on the problem of updating the parameters of a Diazepam PBPK model, using time-concentration human data. Both tools produced very good fits at the individual and population levels, despite the fact that GNU MCSim is not able to consider multivariate distributions. Stan outperformed GNU MCSim in sampling efficiency, due to its almost uncorrelated sampling. However, GNU MCSim exhibited much faster convergence and performed better in terms of effective samples produced per unit of time.

Entities:  

Keywords:  Bayesian; Diazepam; GNU MCSim; PBPK; Population pharmacokinetics; Stan

Mesh:

Substances:

Year:  2019        PMID: 30949914     DOI: 10.1007/s10928-019-09630-x

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  20 in total

1.  Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics.

Authors:  I Nestorov
Journal:  Toxicol Lett       Date:  2001-03-31       Impact factor: 4.372

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Postnatal growth considerations for PBPK modeling.

Authors:  Richard H Luecke; Bruce A Pearce; Walter D Wosilait; William Slikker; John F Young
Journal:  J Toxicol Environ Health A       Date:  2007-06

Review 4.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.

Authors:  Andrea N Edginton; Frank-Peter Theil; Walter Schmitt; Stefan Willmann
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-09       Impact factor: 4.481

Review 5.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

6.  A proposed blood circulation model for Reference Man.

Authors:  R W Leggett; L R Williams
Journal:  Health Phys       Date:  1995-08       Impact factor: 1.316

7.  Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM.

Authors:  Grant Langdon; Ivelina Gueorguieva; Leon Aarons; Mats Karlsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-08       Impact factor: 2.953

8.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

9.  Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.

Authors:  Markus Krauss; Kai Tappe; Andreas Schuppert; Lars Kuepfer; Linus Goerlitz
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

10.  Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.

Authors:  Thierry Wendling; Swati Dumitras; Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-01       Impact factor: 2.745

View more
  3 in total

1.  Well-tempered MCMC simulations for population pharmacokinetic models.

Authors:  Frederic Y Bois; Nan-Hung Hsieh; Wang Gao; Weihsueh A Chiu; Brad Reisfeld
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-07-31       Impact factor: 2.745

2.  Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

Authors:  Janak R Wedagedera; Anthonia Afuape; Siri Kalyan Chirumamilla; Hiroshi Momiji; Robert Leary; Mike Dunlavey; Richard Matthews; Khaled Abduljalil; Masoud Jamei; Frederic Y Bois
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-22

3.  Population Pharmacodynamic Modeling of Epoetin Alfa in End-Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach.

Authors:  Ly Minh Nguyen; Calvin J Meaney; Gauri G Rao; Mandip Panesar; Wojciech Krzyzanski
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.